Fig. 1
From: Genetic and immunological biomarkers predict metastatic disease recurrence in stage III colon cancer
a Proportion of patients with oncogenic mutations in KRAS exon 2, mutations in BRAF exon 15, and microsatellite instable (MSI-H) tumors. Gene expression levels of osteopontin, SASH1, and MACC1. Matched non-diseased colon mucosa (n = 33 for KRAS-, BRAF- and MSI-analysis, and n = 79 for mRNA expression) and stage III colon cancer (n = 83). mut, mutated; MMR, mismatch repair; MSS, microsatellite stable; N, normal colon tissue; T, tumor; wt, wild type; analysis by t test. b Staining for Tumor-infiltrating T-cells (TILs) by immunocytochemistry on tissue sections. c Intratumoral densities of CD3 and CD8 T-cells, threshold for prognostic analysis. d Density of CD3 and CD8 TILs is highly significantly correlated (p < 0.0001; Spearman)